Oculis Holding AG (OCS) EBT Growth (1y) (2023 - 2026)

Oculis Holding AG (OCS) EBT Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 88.57%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 213.87%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.48%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 530.43%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 96.45%
10 Oculis Holding AG 879.09 Mn 590.21 Mn - 60.56%

Historic Data

Download Data
DateValue
Jun 30, 2026 60.56%
Mar 31, 2026 -0.10%
Dec 31, 2025 10.11%
Sep 30, 2025 9.57%
Jun 30, 2025 -33.33%
Mar 31, 2025 -100.69%
Dec 31, 2024 -133.82%
Sep 30, 2024 -117,219.62%
Jun 30, 2024 -62.11%
Mar 31, 2024 62.91%
Dec 31, 2023 -47.75%
Sep 30, 2023 -92.66%
Jun 30, 2023 -11.13%